Immunosuppressive disease is independently associated with significantly shorter survival among patients with CSCC receiving ICI therapy.
A randomized phase 2 maintenance strategy with cabozantinib 60 mg daily for up to 2 years failed to improve 4-month PFS ...
Adding lenvatinib to pembrolizumab improved PFS (6.2 vs 2.8 months; HR 0.64) and ORR (46.1% vs 25.4%) versus pembrolizumab ...
Black Diamond Therapeutics (NASDAQ:BDTX) used a presentation at the 46th annual TD Cowen Healthcare Conference to highlight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results